Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
The effect of pretreatment with the peroxisome proliferator-activated receptor (PPAR) agonist, rosiglitazone, on radioiodine uptake and serum thyroglobulin levels in a patient with radioiodine-resistant papillary thyroid cancer is described. Treatment with rosiglitazone resulted in enhanced radioiodine uptake in areas of presumed metastatic disease in the neck that were previously only faintly seen, and serum thyroglobulin fell from a pretreatment level of 41 ng/mL to less than 2 ng/mL.
Elias
Alan N
AN
Department of Medicine, University of California at Irvine, Medical Center, Orange, 92868, USA. anelias@uci.edu
Lizotte
Paul
P
D002454:Cell Differentiation; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000473:pathology; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists; D011877:Radionuclide Imaging / Q000295:instrumentation / Q000379:methods*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*
D007457:Iodine Radioisotopes; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013954:Thyroglobulin